Item 9 Labs Corp.
INLB · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.27 | 0.01 | -0.00 |
| FCF Yield | 1.60% | 3.01% | -10.82% | -4.32% |
| EV / EBITDA | -15.62 | -51.41 | -46.91 | -4.25 |
| Quality | ||||
| ROIC | -3.39% | -1.41% | -1.70% | -15.88% |
| Gross Margin | 56.13% | 65.66% | 52.40% | 16.14% |
| Cash Conversion Ratio | -0.03 | -0.09 | 0.41 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.35% | 12.20% | 28.80% | 38.88% |
| Free Cash Flow Growth | -71.29% | 122.67% | 18.56% | 20.56% |
| Safety | ||||
| Net Debt / EBITDA | -13.47 | -39.57 | -33.98 | -1.79 |
| Interest Coverage | -1.00 | -0.62 | -0.86 | -5.77 |
| Efficiency | ||||
| Inventory Turnover | 1.16 | 0.74 | 1.23 | 1.36 |
| Cash Conversion Cycle | -184.98 | -188.57 | -156.98 | -92.97 |